The Canadian Centre for Applied Research in Cancer Control (ARCC) is pleased to announce that its 11th annual conference, ARCC2022, will take place virtually on May 16-17, 2022. The objective of this conference is to bridge a connection between researchers and decision-makers, using health economics, services, policy and ethics research to improve cancer control and the delivery of cancer care.
Abstract submission for ARCC2022 is NOW OPEN – Click here to submit your abstract!
Abstract Deadline: Friday January 28, 2022
Presentation Notification: ~Monday March 7th, 2022
Questions? Contact us at email@example.com
Historically, ARCC has offered travel support for students and/or new professionals attending at our conference. With the switch to a virtual format, we will not be offering travel awards this year, but want to let you know we are working on developing a program to offer additional awards and supports at ARCC2022.
To be eligible for an award, the student or new professional must be submitting an abstract to and presenting at the ARCC2022. We will provide additional details in the coming months – and invite any suggestions you may have for how we can support trainees at ARCC2022. Email us at ARCC@cc-arcc.ca or contact Rebecca at Rebecca.Mercer@ontariohealth.ca
**If you are a patient looking to attend the 2022 ARCC Conference, please email Rebecca.Mercer@ontariohealth.ca regarding complementary registration availability
Stay tuned for speakers and information!
Mr. Riaz Alvi, MSc (Co-Chair)
Riaz is the Director of Epidemiology and Performance Measurement at the Saskatchewan Cancer Agency. As well, he is an Adjunct Faculty Member with the University of Saskatchewan’s College of Graduate Studies, Department of Community Health and Epidemiology. He is also the founding Scientific Director of Saskatchewan PATH, a provincial partner of CanPath (the Canadian Partnership for Tomorrow’s Health)
A graduate of the University of Saskatchewan, Riaz has been with the Saskatchewan Cancer Agency for over 20 years, leading the Epidemiology and Performance Measurement team for over half of that time. His portfolio includes cancer surveillance, program evaluation, analytics, and performance measurement across the spectrum of cancer control. His interests include: health services research, patient reported outcomes, health equity, Real World Evidence, cancer prevention and early detection, and cancer in Indigenous populations.
Dr. Kelvin Chan, MD, FRCP, MSc, PhD - (ARCC Co-Director)
Dr Kelvin Chan is a Medical Oncologist at the Sunnybrook Odette Cancer Centre, an Associate Professor at the University of Toronto, and an associate scientist at the Sunnybrook Research Institute. He specializes in GI oncology and Head and Neck oncology. He has recently completed his PhD in Biostatistics (focusing on statistical methods in health economic evaluations) at the Dalla Lana School of Public Health, University of Toronto.
As a clinical epidemiologist and biostatistician, Dr. Chan’s research interests include health services research, health technology assessment, meta-analysis including network meta-analysis, cost-effectiveness analyses, and statistical methods research in health economics. He is the Co-Director at the Canadian Centre for Applied Research in Cancer Control (ARCC), funded by the Canadian Cancer Society (CCS).
Professionally, Dr Chan has an interest in cancer drug reimbursement related issues. He is a member of multiple provincial and national committees related to cancer drug assessments and recommendations including membership at the pan-Canadian Oncology Drug Review (pCODR) Expert Review Committee (pERC), the Committee to Evaluate Drug (CED) and the Interim Chair for the Ontario Steering Committee of Cancer Drugs (OSCCD), Ontario MOHLTC and Cancer Care Ontario. He is also the Clinical Lead for the Provincial Drug Reimbursement Programs (PDRP) at Cancer Care Ontario (CCO).
Dr. Winson Cheung, MD, MPH, FRCPC (Co-Chair)
Winson Y. Cheung, MD, MPH, FRCPC, is a medical oncologist and a nationally and internationally recognized health services and outcomes researcher. He is currently appointed as a Professor of Medicine and Oncology in the Departments of Medicine and Oncology at the University of Calgary where he is also the Chair and Provincial Director of the Health Services Research Program for Cancer Control Alberta.
He is the recipient of numerous accolades for his work to improve health services delivery, quality of life, resource utilization, and costs throughout the cancer continuum, including the National Cancer Institute of Canada Dorothy Lamont Award, the Novartis Oncology Young Canadian Investigator Mentor Award, the Multinational Association of Supportive Care in Cancer Investigator Award, and several merit awards from the American Society of Clinical Oncology. He has secured over 15 million dollars in grant funding.
Dr. Cheung’s primary research interest is discovering and operationalizing new methods of cancer care delivery, including implementing strategies to improve the efficacy and real world effectiveness of diagnostic and therapeutic interventions. His projects focus on understanding the interplay of various patient, physician, and system level factors as well as innovative models of care that drive practice patterns in the real world setting and learning how processes can be modified to better inform care, especially for vulnerable segments of the population (e.g. immigrants, those with low socioeconomic status, and older patients). The overarching goal of his work is to ensure that cancer care is appropriately accessed and provided to all patients. To date, he has published over 200 peer-reviewed manuscripts.
Dr. Manraj Kaur, PT, PhD (Student & New Professional Representative)
Manraj Kaur is a Canadian Institutes of Health Research’s postdoctoral fellow at the Patient-Reported Outcomes, Value and Experience (PROVE) Center, Brigham and Women’s Hospital and is cross-appointed at Harvard Medical School, Boston, United States. Her value-based healthcare-relevant research focuses on breast cancer programs using methods of decision science and economic evaluation, including preference assessment. For her doctoral thesis, Manraj completed the development of a preference-based instrument for assessing healthcare interventions in women diagnosed with breast cancer (BREAST-Q Utility module). During her postdoctoral fellowship, she will assess the psychometric properties of the Utility module and develop preference weights. Dr Kaur is also interested in understanding and measuring the impact of cancer diagnosis and treatment interventions on the health-related quality of life using patient-reported outcome instruments using modern psychometric methods.
Ms. Valerie McDonald, MSW (Patient & Family Representative)
Valerie McDonald earned her MSW from the University of Toronto and currently works as a free-lance writer and editor. Valerie’s interest in cancer is deeply personal. Within a five year period, her eldest daughter was treated for Burkitt’s Lymphoma, her mother died of lung cancer, and her second daughter died after relapsing on treatment for Acute Lymphoblastic Leukemia. She has volunteered in many capacities in the health care sector since 1996 to promote family and patient partnerships and to advocate for more effective palliative care. As a writer and researcher, Ms. McDonald worked on initiatives led by the Centre for Effective Practice for the Ontario Ministry of Health, CAMH, and Cancer Care Ontario. She has developed family resources for the Canadian Cancer Society and Canadian Virtual Hospice. She served as patient member on CADTH’s pan-Canadian Oncology Drug Review Expert Review Committee (pERC) for six years.
Dr. Rebecca Mercer, PhD (ARCC Network Manager)
Rebecca Mercer is the Network Manager for the Canadian Centre for Applied Research in Cancer Control (ARCC). Rebecca works as a Research Lead with Ontario Health, under the Provincial Drug Reimbursement Programs. She has significant experience with knowledge translation, and an interest in facilitating information transfer among stakeholders. Rebecca received her PhD in Medical Genetics from the University of Alberta in 2012, and also holds an Honours BSc in Biomedical Sciences from the University of Guelph.
Dr. Stuart Peacock, DPhil - (ARCC Co-Director)
Stuart Peacock holds the Leslie Diamond Chair in Cancer Survivorship and is a Professor in the Faculty of Health Sciences, Simon Fraser University. He is currently Co-Director of the Canadian Centre for Applied Research in Cancer Control (ARCC). ARCC is a pan-Canadian research centre providing interdisciplinary leadership in health economics, services, policy and ethics research. Stuart is also a Distinguished Scientist in Cancer Control Research at the BC Cancer Agency, a member of the Board of Directors of the Canadian Agency for Drugs and Technologies in Health, and past President of the International Society on Priorities in Health Care. He has held university positions in Canada, Australia and the UK. Over the past 20 years, Stuart’s main research interests have focused on research into developing more effective cancer services, making health system funding decisions fairer and more transparent, and improving the quality of life of cancer patients and survivors.